Cogent Biosciences, Inc. cash flow statement

In fiscal 2020, Cogent Biosciences, Inc.'s operations generated −$35.9m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cogent Biosciences, Inc.: cash flow statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020
Cash from operations	−26	−32	−42	−36
Depreciation and amortisation	1	1	1	1
Stock-based pay	1	3	3	6
Capital spending	1	1	0	—
Free cash flow	−27	−33	−42	—
Free cash flow after stock pay	−28	−36	−45	—
Shares issued	0	1	0	25

US$ millions unless shown otherwise. Fiscal quarters.

Cogent Biosciences, Inc.: cash flow statement, quarterly
Quarter	2019 Q1Mar 2019	2019 Q2Jun 2019	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020
Cash from operations	−12	−11	−10	−8	−8	−8	−10	−9
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	1	1	1	1	1	1	4	1
Capital spending	0	0	−0	0	—	—	—	—
Free cash flow	−12	−11	−10	−8	—	—	—	—
Free cash flow after stock pay	−12	−12	−11	−9	—	—	—	—
Shares issued	0	0	0	0	0	0	11	14

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cogent Biosciences, Inc.